Erin Kempe, DO
Allergy & Immunology · Fort Collins, CONPI 1790005692
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.1% of the total across 104 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 20.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $645, 3.4 times the $191 reported in 2019. That places this record below the midpoint for allergy & immunology clinicians in CO, where the typical reported total is $2,675.
Across 104 payments — averaging $23.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$504
- Regeneron Healthcare Solutions, Inc.$336
- GSK$298
- Takeda Pharmaceuticals U.S.A., Inc.$220
- CSL Behring$184
- Pfizer$175
- plus $703 from 16 others
What the payments were for
- Food & beverage$2,34997%
- Education$713%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 16 | $504 |
| Regeneron Healthcare Solutions, Inc. | 15 | $336 |
| GSK | 14 | $298 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $220 |
| CSL Behring | 9 | $184 |
| Pfizer | 10 | $175 |
| Sanofi | 5 | $95 |
| Derma Sciences, Inc. | 1 | $95 |
| Optinose US, Inc. | 2 | $95 |
| Lilly USA, LLC | 3 | $69 |
| Incyte Corporation | 3 | $58 |
| Genentech USA, Inc. | 3 | $42 |
| Teva Pharmaceuticals USA, Inc. | 2 | $41 |
| Biocryst US Sales Co., LLC | 2 | $32 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $32 |
| Kaleo, Inc. | 1 | $27 |
| AbbVie | 1 | $25 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| Amgen | 1 | $20 |
| Novartis | 1 | $19 |
| Hospira, Inc. | 1 | $16 |
| Grifols USA, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$110
How this compares
$2,421 in reported general payments places this provider in the 45th percentile of 89 allergy & immunology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 49 | $232,954 |
| Dupixent PenDupilumab | 30 | $117,445 |
| NucalaMepolizumab | 13 | $48,910 |
| Dupixent SyringeDupilumab | 13 | $48,083 |
| Advair HfaFluticasone Propion/Salmeterol | 51 | $28,500 |
| DuleraMometasone/Formoterol | 47 | $17,772 |
| SymbicortBudesonide/Formoterol Fumarate | 64 | $15,969 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $11,141 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $10,002 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 40 | $8,636 |
| Arnuity ElliptaFluticasone Furoate | 17 | $5,599 |
| Fluticasone-Salmeterol HfaFluticasone Propion/Salmeterol | 11 | $5,501 |
| Epinephrine | 23 | $5,208 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 21 | $3,943 |
| Qvar RedihalerBeclomethasone Dipropionate | 14 | $3,104 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCGamunex-C | $13 | $232,95449 claims |
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $298 | $75,65257 claims |
| AstraZenecaSymbicort | $504 | $15,96964 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $41 | $3,10414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 89 allergy & immunology providers in Colorado.
Other allergy & immunology in Fort Collins
- James FultonFort Collins$21K
- Michael MartucciFort Collins$17K
- William CulverFort Collins$9K
- Erin WillitsFort Collins$6K
- Krishna MurthyFort Collins$892
- Velusamy KailasamFort Collins$885
- Rohit KatialDenver$758K
- Nicole BarberisLakewood$351K
- Christopher WebberColorado Springs$350K
- Jeffrey RumbyrtLakewood$348K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.